Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics
SYRS Price/Volume Stats
Current price | $5.35 | 52-week high | $8.17 |
Prev. close | $5.84 | 52-week low | $2.09 |
Day low | $5.15 | Volume | 318,200 |
Day high | $5.90 | Avg. volume | 198,903 |
50-day MA | $6.85 | Dividend yield | N/A |
200-day MA | $4.57 | Market Cap | 112.71M |
SYRS Stock Price Chart Interactive Chart >
SYRS POWR Grades
- Sentiment is the dimension where SYRS ranks best; there it ranks ahead of 69.53% of US stocks.
- The strongest trend for SYRS is in Growth, which has been heading down over the past 26 weeks.
- SYRS ranks lowest in Momentum; there it ranks in the 18th percentile.
SYRS Stock Summary
- Of note is the ratio of SYROS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 7.4% of US stocks have a lower such ratio.
- SYRS's price/sales ratio is 16.91; that's higher than the P/S ratio of 93.57% of US stocks.
- Revenue growth over the past 12 months for SYROS PHARMACEUTICALS INC comes in at -62.47%, a number that bests merely 3.5% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to SYROS PHARMACEUTICALS INC are ABUS, STTK, VIR, SPRB, and SYBX.
- Visit SYRS's SEC page to see the company's official filings. To visit the company's web site, go to www.syros.com.
SYRS Valuation Summary
- In comparison to the median Healthcare stock, SYRS's price/sales ratio is 345.24% higher, now standing at 18.7.
- Over the past 91 months, SYRS's EV/EBIT ratio has gone up 8.7.
Below are key valuation metrics over time for SYRS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SYRS | 2023-12-29 | 18.7 | 4.5 | -1.6 | -1.1 |
SYRS | 2023-12-28 | 17.2 | 4.2 | -1.4 | -1.0 |
SYRS | 2023-12-27 | 17.5 | 4.2 | -1.5 | -1.0 |
SYRS | 2023-12-26 | 16.8 | 4.1 | -1.4 | -0.9 |
SYRS | 2023-12-22 | 16.8 | 4.1 | -1.4 | -1.0 |
SYRS | 2023-12-21 | 13.8 | 3.4 | -1.2 | -0.7 |
SYRS Growth Metrics
- The 5 year net cashflow from operations growth rate now stands at 7.16%.
- The year over year cash and equivalents growth rate now stands at -67.74%.
- The 3 year net cashflow from operations growth rate now stands at -84.69%.
The table below shows SYRS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 23.436 | -114.951 | -113.693 |
2022-06-30 | 25.242 | -107.291 | -109.467 |
2022-03-31 | 24.128 | -107.567 | -97.476 |
2021-12-31 | 23.488 | -99.54 | -86.558 |
2021-09-30 | 21.385 | -106.495 | -92.875 |
2021-06-30 | 19.516 | -93.623 | -86.334 |
SYRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SYRS has a Quality Grade of C, ranking ahead of 31.76% of graded US stocks.
- SYRS's asset turnover comes in at 0.093 -- ranking 271st of 682 Pharmaceutical Products stocks.
- ONVO, OPK, and ICPT are the stocks whose asset turnover ratios are most correlated with SYRS.
The table below shows SYRS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.093 | 1 | -1.040 |
2021-03-31 | 0.093 | 1 | -1.148 |
2020-12-31 | 0.092 | 1 | -1.221 |
2020-09-30 | 0.067 | 1 | -0.971 |
2020-06-30 | 0.044 | 1 | -0.838 |
2020-03-31 | 0.026 | 1 | -0.889 |
SYRS Price Target
For more insight on analysts targets of SYRS, see our SYRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $17.29 | Average Broker Recommendation | 1.44 (Moderate Buy) |
Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsCAMBRIDGE, Mass., December 19, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 p |
individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last weekKey Insights Syros Pharmaceuticals' significant individual investors ownership suggests that the key decisions are... |
Syros (SYRS) Rises on Upbeat Initial Study Data on TamibaroteneSyros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia. |
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineCAMBRIDGE, Mass., December 06, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia |
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside PotentialIf the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. |
SYRS Price Returns
1-mo | -27.11% |
3-mo | -31.32% |
6-mo | 35.44% |
1-year | 91.76% |
3-year | -92.81% |
5-year | -94.15% |
YTD | -31.32% |
2023 | 116.99% |
2022 | -88.99% |
2021 | -69.95% |
2020 | 57.02% |
2019 | 24.06% |
Continue Researching SYRS
Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...